Search

News by Month

News Categories


Clinical Predictive Leader Jvion Closes Growth Round of Funding

Atlanta, GA (PRWEB) – Jvion, the market leader in clinical predictive analytics, announced the closing of a growth round of funding led by Eastside Partners, with participation from existing investor Martin Ventures. The funds will be used to support the company’s rapidly growing customer base and accelerate its technology and product roadmap.

“Jvion is experiencing significant growth and we are excited to lead this round of investment,” said Eastside’s managing partner Emerson Fann. “The technology that drives Jvion’s RevEgis clinical predictive solution is impressive in terms of its accuracy, flexibility and the ease with which it integrates into existing clinical workflows. The Jvion team is combining clinical concepts, healthcare intelligence, and socioeconomic context into an advanced machine learning engine that has the potential to completely change the way we think about clinical interventions.”

Jvion has internally funded its growth over the last several quarters as a result of strong customer demand. This round of funding will further accelerate growth and provide additional development resources for the company’s RevEgis patient phenotype predictive platform. “We are grateful to our investors for this recent funding,” said Jvion CEO Shantanu Nigam. “This capital will help us enhance the RevEgis solution to meet growing demand for accurate, nimble, and scalable predictive solutions that help providers across the continuum better focus care and drive improved quality outcomes.”

Government penalties, the shift to value-based models of care and reimbursement, and the rise of consumerism are all putting pressure on providers to improve health outcomes while reducing the overall cost of care. In response, the provider market is actively seeking real-time predictive analytic solutions that can better target rising risk individuals inside and outside of the hospital. Over 2015, Jvion saw the company’s client base more than double and significant expansion in the number of patient lives improved by Jvion’s RevEgis predictive engine.

“We started Jvion with a mission to leverage new technologies and the power of data to improve patient lives. We work to drive the highest returns for our provider clients and the patients they serve. And we do this by more accurately predicting avoidable high-cost, high-risk conditions and better enabling effective interventions inside the hospital and outside in the community,” said Nigam. “We will use this round of investment to enhance our compliment of use cases. By adding additional diseases and conditions to the RevEgis engine, we will extend our aim of improving patient lives across inpatient, post-acute, and community/outpatient settings. It is our goal to use data, machine learning capabilities, and advanced Clinical Patient Pod (CPP) technology to change the way we as a healthcare community think about and deliver patient care.”